About Us

4

Meet The Team

Nuevocor’s LMNA gene therapy is based on decades of research into fundamental mechanisms underlying LMNA-associated disease enabled by the development of novel technologies on the part of co-founders Colin Stewart and Brian Burke. Together with the AAV gene therapy and cardiac disease modeling expertise of scientific co-founders Mark Kay and Jianming Jiang respectively, Nuevocor is well-positioned to cure LMNA and other genetic cardiomyopathies, amongst other cardiac diseases. 

YC Headshot2022.jpg

Yann Chong Tan, PhD

Founder and CEO

Extensive experience in the biotech space, successful inventor and entrepreneur who co-founded a Nasdaq-listed biotech, Atreca.

WhatsApp Image 2021-06-03 at 10.04.52 AM

Euan Ashley, MD, PhD

Scientific Advisory Board Member

Leading medical geneticist and cardiologist at Stanford University.
Co-founder of Personalis and other companies.

Professor of Medicine and Genetics at Stanford University  

WhatsApp Image 2021-05-25 at 10.40.54 AM

Brian Burke, PhD

Co-Founder and Scientific Advisory Board Member

Distinguished cell biologist in the area of the nuclear envelope, including lamins and the LINC complex, through the innovative use of microscopic and biochemical technologies.

Research Director at the Agency for Science, Technology and Research, Singapore

Mia Hu.jpg

Mia Hu, PhD

Board Member

Healthcare investor and incubator with extensive research experience in regenerative medicine.

Associate Director of Boehringer Ingelheim Venture Fund

WhatsApp%20Image%202021-05-25%20at%203.5

Jianming Jiang, PhD

Co-Founder

Emerging leader in investigating the regulatory mechanisms underlying cardiovascular disease through the use of AAV vectors and other cutting-edge technologies.

Asst. Prof. in Biochemistry at the National University of Singapore

WhatsApp%20Image%202021-06-03%20at%207.0

Mark Kay, MD, PhD

Co-Founder and Scientific Advisory Board Member

World expert in the area of gene therapy technologies for the treatment of genetic and acquired diseases, including the discovery of novel adeno-associated virus (AAV) capsids.

Head of the Division of Human Gene Therapy; and Professor of Pediatrics and Genetics at Stanford University

OhDearStudio_ Nuevocor_071_edited_edited

Cheryl Lee

Director,
Project Management

Accumulated experience in research project and funding management as administrative and operations lead for both research grantees and grant funder in the Singapore public sector.

Yin Loon Headshot.jpg

Yin Loon Lee, PhD

Co-Founder and Senior Director, Biology

As a postdoctoral fellow with Brian Burke, investigated mechanism of disease in laminopathies, and contributed to development of Nuevocor's technology.

OhDearStudio_ Nuevocor_081_edited.jpg

Hendrikje Werner, PhD

Principal Scientist

As a postdoctoral fellow with Colin Stewart, played pre-eminent roles in studies that resulted in Nuevocor’s lead program as well as its target discovery platform.

WhatsApp Image 2021-07-29 at 2.40.36 PM.jpeg

David Russell

Chief Scientific Advisor

Expert on viral gene therapy and biology, and genetic manipulation of stem cells. Founded and sold Universal Cells, a biotech company built on technologies developed in his academic lab.

Professor Emeritus of Medicine at University of Washington

OhDearStudio_ Nuevocor_098_edited.jpg

Idina Shi, PhD

Director, Operations and Business Development

Combined business development and corporate strategy experience through tenures as biotechnology portfolio manager and science policy official in Singapore government science agency.

WhatsApp Image 2021-05-25 at 11.10.03 AM

Colin Stewart, PhD

Co-Founder and Scientific Advisory Board Member

Pioneer in techniques underpinning mouse experimental genetics, and developer of multiple mouse models for laminopathies for elucidating mechanisms of disease.

Research Director at the Agency for Science, Technology and Research, Singapore

Careers

Please visit Nuevocor’s LinkedIn page to view our job listings by clicking here.

When you're ready, please click: